Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5500 - Strategy to improve the antitumor efficacy of dendritic cell-based nanovaccine under magnetic field control

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Oleksandr Gorbach

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

O. Gorbach1, N. Khranovska1, O. Skachkova1, M. Inomistova1, I. Shumeiko1, V. Orel2

Author affiliations

  • 1 Experimental Oncology, National Cancer Institute of the MPH Ukraine, 3022 - Kiev/UA
  • 2 Research Laboratory Of Medical Physics And Bioengineering, National Cancer Institute of the MPH Ukraine, 3022 - Kiev/UA
More

Resources

Abstract 5500

Background

One of the approaches for increasing DC vaccine efficacy is the direct delivery of generated DC to the regional lymph nodes and tumor site. The aim was to investigate the antitumor efficacy of DC loaded with tumor antigens and iron oxide nanoparticles (INP) under the influence of an external magnetic field.

Methods

In experimental study, 60 CBA mice were involved. Sarcoma 37 (S37) was used as experimental tumor model, and cells in lethal dose (9*105 cells per animal) were injected into the hip. DCs were obtained from syngeneic mice splenocytes and loaded by mechanically modified lyophilized Sa 37 cells (0.05 mg/ml) with Fe2O3 nanoparticles (8x10-12 g/cell, Sigma-Aldrich). DC vaccine was injected intradermally 3 times with three-day interval starting on the 7th day after tumor transplantation. After DC administration, animals were exposed under magnetic field for 1 hour. Tumor volume was evaluated with three days interval starting after 10 days of tumor transplantation. Tumor mass, leukocyte formula of the peripheral blood and absolute number of cells in the lymphoid organs of animals were assessed at the 25th day of the experiment. The expression levels of GAPDH, FOXP3, VEGF-a, IL-10, TGF-b, IFNγ and IL-4 genes were analyzed in tumor, spleen and regional lymph nodes using a quantitative PCR method.

Results

The application of generated DCs with INP promoted a reduction of primary tumor volume compared to the control group (p = 0,022) and DC monotherapy (p = 0.005). DCs with INP didn’t significantly effect on the hematological parameters in mice with S37. The combined effect of DCs with INP reduced mRNA expression levels of FoxP3 by 1.9 times (p = 0.04), VEGF-α by 2.9 times (p = 0.02), IL-10 by 2.9 times (p = 0.005) and TGF-β by 10 times (p = 0.002) in tumor cells compared to the control. The administration of DC vaccine with INP led to reduce tumor immunosuppression in the regional lymph nodes, namely FoxP3 mRNA level decreased in 2,4 times and Il-10 mRNA level – in 1.9 times compared to the control group, p = 0.012.

Conclusions

Application of DC vaccine with INP under magnetic field resulted in a pronounced antitumor effect in tumor-bearing mice.

Clinical trial identification

Legal entity responsible for the study

National cancer institute of the MPH Ukraine.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.